The SAFE Act adds a permanent, class‑based Schedule I(e) for “fentanyl‑related substances” to the Controlled Substances Act, using specified structural modifications to define the class. It also carves fentanyl‑related substances out of certain quantity‑based mandatory minimum calculations, amends criminal thresholds for fentanyl and certain analogues, and requires the Attorney General to publish identified substances.
Beyond scheduling, the bill rewrites the pathway for removing or rescheduling a fentanyl‑related substance: the Secretary of Health and Human Services makes a scientific and medical determination that is binding on the Attorney General, who must act within 90 days. The bill also creates multiple procedural changes to speed legitimate research (a notice‑based registration track, continuation rules when a substance is newly scheduled, limited incidental manufacturing for research), provides limited retroactive sentence relief if a substance is later removed or rescheduled, requires an interim rulemaking deadline, and directs a GAO review of the policy’s effects within four years.
At a Glance
What It Does
Creates a Schedule I(e) that sweeps in compounds structurally related to fentanyl, directs the Attorney General to publish identified substances, removes these classed substances from selected quantity‑based mandatory minimums, binds the DEA to HHS scientific findings on rescheduling, and establishes expedited procedures to allow research with Schedule I substances under notifications rather than full new registrations.
Who It Affects
Federal prosecutors and federal sentencing outcomes in opioid cases, DEA and HHS personnel who will implement scheduling and rescheduling processes, forensic toxicology labs and coroners who must identify a wider range of compounds, academic and industry researchers developing opioid products, and individuals previously convicted of offenses involving substances later removed or rescheduled.
Why It Matters
Class scheduling aims to close a regulatory gap that allowed rapid proliferation of new fentanyl analogues, but it also changes interagency power dynamics (HHS determinations bind DEA) and alters the incentives facing prosecutors and researchers. The research and resentencing provisions attempt to preserve legitimate science and mitigate unfair penalties if a substance is later downgraded.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a new Schedule I(e) entry to the Controlled Substances Act that covers any substance meeting a list of structural modifications relative to fentanyl (for example: substitutions on the phenethyl group, changes to the piperidine ring, replacement of the aniline ring, or replacement of the N‑propionyl group). The Attorney General must publish an itemized list of substances the agency determines meet that structural definition within 60 days of each determination, but the statutory definition itself controls whether a substance is scheduled even if it does not appear on the published list.
On penalties, the SAFE Act withdraws fentanyl‑related substances from certain quantity‑based mandatory minimum penalty provisions, while simultaneously adjusting the numeric quantity thresholds that trigger mandatory minimums for fentanyl and for individually scheduled fentanyl analogues. The import/export provisions receive parallel threshold amendments.
The practical effect is that the statute distinguishes between (1) fentanyl itself, and (2) individually scheduled fentanyl analogues, which remain subject to quantity thresholds, and (3) the class of fentanyl‑related substances, which are not subject to the named quantity‑based mandatory minimum provisions.To enable timely correction where a substance should not remain a Schedule I drug, the bill creates a new 201(k) process: the Secretary of Health and Human Services prepares a written scientific and medical evaluation and, where the Secretary finds the substance has abuse potential lower than Schedule V or lower than Schedules I and II, that finding is binding on the Attorney General. The Attorney General then has 90 days to remove the substance from Schedule I entirely or to reschedule it (to Schedule III when the Secretary supports that move).
The statute requires a 30‑day notice from the Secretary before sending the evaluation to DEA, includes a treaty‑obligation exception, establishes identification and notification duties for DEA, and preserves ordinary petition channels.The research provisions lower administrative friction for legitimate studies involving Schedule I material. Registered researchers can notify DEA and proceed after specified short windows (or, for applicants without prior Schedule I/II research registrations, receive registration or an order to show cause within a 45‑day window).
The bill allows institutions to use a single registration across several nearby sites, permits agents or employees to work under a registered researcher without separate registrations (with institutional notice and authorization), allows limited manufacturing activities incident to research (but not cultivation of marijuana), and lets ongoing research continue if a substance is newly scheduled while a researcher is already working with it—subject to prompt registration and expedited administrative review. The Attorney General must also publish on the DEA website any special processes or differing criteria applied to particular schedule I substances.
The Five Things You Need to Know
Section 202(c)(e) creates Schedule I(e): a class entry based on five structural modifications to fentanyl (phenyl replacement, phenethyl substitutions, piperidine substitutions, aniline ring replacement, and acyl group replacement).
The Attorney General must publish a list of identified fentanyl‑related substances within 60 days of determining they meet the statutory structural definition; absence from the list does not mean the compound is uncontrolled if it meets the definition.
The bill exempts fentanyl‑related substances from specific quantity‑based mandatory minimum penalty provisions (cross‑references to particular clauses in 21 U.S.C. 841(b)(1) and 21 U.S.C. 960(b)), while keeping numeric mandatory thresholds for fentanyl and individually scheduled analogues.
Under the new 201(k) process the Secretary of HHS makes a scientific/medical determination that is binding on the Attorney General, and the Attorney General must issue an order removing or rescheduling the substance within 90 days of receiving that evaluation.
The research pathway (new 21 U.S.C. 823(m)) lets practitioners with current Schedule I/II research registrations begin work 30 days after notifying DEA, and requires DEA to register new applicants or issue an order to show cause within 45 days after a complete notice/application.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Permanent class scheduling for fentanyl‑related substances
Adds a Schedule I(e) class entry that defines 'fentanyl‑related substance' by enumerating five categories of structural modification relative to fentanyl. The provision captures salts, isomers, and possible salts of isomers, and clarifies that a substance meeting the structural criteria is controlled unless it is expressly exempted, already listed elsewhere, or later removed via the new 201(k) process. It also requires DEA to publish an itemized list of substances identified under the definition within 60 days of each determination.
Domestic penalty thresholds and carve‑outs
Rewrites numeric quantity triggers in the domestic mandatory‑minimum table for fentanyl and for analogues that are individually scheduled, but explicitly carves fentanyl‑related substances (the new class) out of those particular clauses. Practically, prosecutors retain quantity thresholds for fentanyl and for certain listed analogues, while the classed substances are removed from those specified mandatory minimum calculations—creating a two‑track penalty structure for fentanyl‑type offenses.
Import/export thresholds aligned with domestic changes
Mirrors the numeric threshold amendments from domestic law in the import/export statute and inserts the same carve‑out language for fentanyl‑related substances. The effect is parallel treatment of cross‑border trafficking: fentanyl and listed analogues trigger the numeric thresholds, while classed compounds do not fall within the same named quantity‑based mandatory minimum text.
HHS‑led removal/rescheduling process that binds the Attorney General
Creates a new procedure where the Secretary of HHS may determine a fentanyl‑related substance has lower abuse potential (including standards for evidence: receptor binding, in vitro functional assays, and in vivo animal behavioral studies). The Secretary's scientific and medical evaluation is binding on the Attorney General, who then must remove or reschedule the substance within 90 days. The subsection includes: advance notice to DEA, a treaty‑obligation exception, obligations for DEA to identify and notify HHS when DEA believes a substance is classed, petition procedures, and a provision allowing HHS to contract for studies.
Retroactive sentence relief where a substance is later removed or rescheduled
Authorizes sentencing courts to vacate or reduce previously imposed sentences for offenses involving a substance that was a fentanyl‑related substance at the time of the offense but subsequently was removed from that designation and placed on a less restrictive schedule or removed entirely. Motions may be made by defendants, BOP, the government, or the court on its own motion; the defendant need not be present at any such hearing.
Expedited research registration, single‑site registrations, and limited manufacturing for research
Adds an alternate notice‑based pathway (new 21 U.S.C. 823(m)) for certain Schedule I research tied to FDA investigational drug applications or federal funding: registered applicants can notify and begin after an abbreviated period, new applicants get a 45‑day window for registration or an order to show cause, and DEA must accept electronic submissions. The section also allows agents and employees to operate under an institutional registered researcher's registration with notice and authorization, permits single registrations to cover multiple nearby sites under the same institution, allows limited manufacturing activities incidental to research (processing into extracts, dosage‑form development), and creates expedited procedures to continue research when a substance is newly scheduled.
Rulemaking authority and GAO review
Directs the Attorney General to issue implementing rules within one year and authorizes interim final rules without a pre‑demonstration of good cause, while preserving notice‑and‑comment post‑issuance. Requires the GAO to report within four years on implementation, research impacts, rescheduling actions, enforcement outcomes, sentencing comparisons, and the efficacy of class scheduling in stemming analogue proliferation—drawing on input from HHS, DOJ, DHS, State, ONDCP, researchers, law enforcement, and justice reform stakeholders.
This bill is one of many.
Codify tracks hundreds of bills on Justice across all five countries.
Explore Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Academic and industry researchers: The notice‑based registration path, single‑registration multi‑site option, allowance for incidental manufacturing, and the continuity rule when a substance is newly scheduled all reduce administrative friction and speed access to Schedule I compounds for regulated clinical and federally funded research.
- Defendants convicted of fentanyl‑related substances: Individuals whose offenses involved a substance later removed or rescheduled may obtain resentencing or sentence vacatur motions, creating a route for sentence reduction when scientific evidence changes.
- Federal public health agencies (HHS, NIH, FDA): The bill centralizes scientific determinations at HHS, giving public‑health experts the primary role in assessing abuse potential and influencing rescheduling outcomes.
Who Bears the Cost
- DEA and Department of Justice: Must implement publication requirements, new class‑scheduling enforcement, expedited registration processes, and an altered interagency workflow where HHS determinations are binding—requiring staff time, rulemaking, and operational change.
- Forensic toxicology labs and coroners: Labs must detect and identify a larger and evolving set of structurally related compounds to support enforcement and public health surveillance, increasing analytical complexity and cost.
- Federal courts and the Bureau of Prisons: The retroactive relief provision may generate a substantial volume of motions and hearings, imposing administrative and adjudicative burdens on courts and potentially creating downstream population and management questions for BOP.
Key Issues
The Core Tension
The central dilemma is speed versus precision: the bill prioritizes rapid, broad control of emergent fentanyl‑related compounds to protect public safety, but that breadth and haste risk sweeping in legitimate research materials, straining forensic capacity, and producing sentencing outcomes that later appear disproportionate—so the statute must balance preventing proliferation against preserving rigorous scientific assessment and fair criminal consequences.
The statutory structural definition is deliberately broad to anticipate chemical variation, but that breadth produces real uncertainty. Forensic chemistry does not always produce quick, unambiguous structural identifications; some compounds may be captured by the definition before laboratories can reliably detect and quantify them, complicating both enforcement and clinical toxicology.
The requirement that the Attorney General publish identified substances within 60 days is procedural clarity, but the statute also makes the written structural definition the controlling element, which means enforcement can proceed even where the published list lags.
Binding HHS determinations shorten the administrative path for downgrading or removing a substance, but they concentrate power over scheduling determinations in a medical/scientific agency rather than the Justice Department. That improves scientific consistency but may create operational friction (e.g., HHS may lack the forensic or interdiction data DOJ uses when deciding appropriate criminal‑law controls).
The bill’s evidence standard for HHS explicitly contemplates receptor binding, in vitro functional assays, and animal behavior tests—studies that take time and resources; smaller academic labs or early‑stage investigators may lack the means to generate them.
Finally, the retroactivity provision raises a practical trade‑off: it mitigates unfairness where a substance is later found to have low abuse potential, but it risks a wave of post‑conviction motions that will consume judicial resources. The research facilitation measures are meaningful for regulated clinical projects tied to FDA applications or federal grants, but they are less directly helpful to curiosity‑driven basic science that lacks those formal sponsor relationships.
The treaty‑obligation exception also preserves international obligations but means that some substances could remain controlled even if HHS finds low domestic abuse potential, creating inconsistencies between the bill’s scientific logic and international constraints.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.